Dana-Farber’s Breast Oncology Center shared a post on X:
“Dr. Sara Tolaney will discuss results of the ASCENT-4 trial during the rapid oral session at ASCO26.
Sunday, May 31
11:30 – 11:36 AM CDT (12:30 – 12:36 PM EST)
Hall D1.”

WSG TP-II Trial: Excellent 5-Year Survival After De-Escalated Neoadjuvant Therapy In HR+/HER2+ Early Breast Cancer
